Unbiased Analysis of Today's Healthcare Issues

Archive for the 'Comparative Effectiveness' Category

The Future of Oncology Treatment and Value Assessment

Value frameworks are all the rage of late.  But are payers really using them? According to my colleague Jeremy Schafer, the answer is yes.  From an article in Drug Topics: “Value assessment may become more important as the health-care market shifts to outcomes and value-based reimbursement models,” said Jeremy Schafer, PharmD, MBA, Senior Vice President […]

Read the rest of this entry »

Does more spending improve outcomes?

A number of studies have claimed that increased health expenditures may result in no better, or even worse outcomes.  For instance, a paper by Fisher et al. (2003) looking at patients with acute myocardial infarction, colorectal cancer, or hip fracture finds that “Quality of care in higher-spending regions was no better on most measures and […]

Read the rest of this entry »

Predicting Real-World Effectiveness of Cancer Therapies Using OS and PFS Clinical Trials Endpoints

Clinical trials for cancer treatments aim to demonstrate whether one treatment is better than another. What is of most interest to patients, providers and payers, however, is which treatment works best in the real-world, not in a randomized controlled trial. Further, clinical trials often use progression free survival to measure treatment outcomes rather than overall […]

Read the rest of this entry »

The Voice of the Patient

Did you ever wonder what is is like having lung cancer?  Or narcolepsy?    What factors are most important to patients when receiving treatment for these diseases? The FDA is working to collect these answers to help guide their drug approval process.  The FDA’s “Voice of the Patient” aims to “…more systematically gather patients’ perspectives […]

Read the rest of this entry »

Presentation at 2017 British Society for Rheumatology

For those attending the British Society for Rheumatology Annual Meeting in Birmingham, England, I will be giving a podium presentation on Wednesday, April 26 at 12pm BST titled “Economic Burden of Rheumatoid Arthritis is Higher for Anti-Citrullinated Protein Antibody-Positive Patients.”  Come by Hall 6 to check it out along with other presentations in the Clinical and […]

Read the rest of this entry »

Applying Cost Effectiveness Analysis to all Health Care Interventions

That is the topic of a Health Affairs blog post published today by James Baumgarder and Peter Neumann.  An excerpt is below. Cost-effectiveness analysis (CEA) is an important tool for assessing and pointing the way toward better health care efficiency. The number of published CEAs on health care interventions has blossomed, averaging 34 per year […]

Read the rest of this entry »

Orphan Medical Products

Should health insurers cover orphan drugs?  Although the clear answer appears to be yes, the issue is tricky.  An orphan drug is one which treats a limited number of people.  In Europe, this designation generally applies to patients with a disease with an overall prevalence between 5 and 10,000 individuals. In order to incentivize innovators […]

Read the rest of this entry »

Patient Engagement in Cost Effectiveness Research

Cost effectiveness research aims to determine if the benefits of a treatment outweigh the cost.  But which benefits should be included?  How should we weight improvements in different outcomes?  What data and methods need to be used to measure benefits and costs? These are questions that academics typically think of as within the domain of […]

Read the rest of this entry »

What is the value of a QALY?

Many new treatments deliver significant benefits to patients.  In many cases, however, the new treatments may be more expensive.  How do we know if a treatment is worth the cost? Cost effectiveness analysis helps us answer this question.  Cost is fairly easy to calculate but benefits are more complicated.  A treatment could extend a person’s […]

Read the rest of this entry »

Do pharmaceuticals have value to healthy people?

Value-based pricing has become all the rage of late among health policy wonks. Medicare aims to tie 90% of reimbursement to some measure of value by 2018. The AMA has endorsed value-based pricing for pharmaceuticals. Organizations such as IVI and ICER propose different approaches for measuring value as well. Typically, value is measured as the […]

Read the rest of this entry »